PFWS

Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal

Retrieved on: 
Monday, September 19, 2022

DAXXIFY demonstrated long-lasting efficacy in all subgroups, consistent with the overall population results of the SAKURA clinical trials.

Key Points: 
  • DAXXIFY demonstrated long-lasting efficacy in all subgroups, consistent with the overall population results of the SAKURA clinical trials.
  • Efficacy and safety were analyzed by age (18-45, >45-55, and >55 years) and race (Asian, Black/African American, and White).
  • DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study.
  • A large, open-label, phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study.

Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery

Retrieved on: 
Wednesday, September 1, 2021

The peer-reviewed publication reported efficacy data from a post-hoc analysis of the SAKURA Phase 3 clinical program that demonstrated significant, progressive improvement in static glabellar lines with repeated treatment of DaxibotulinumtoxinA for Injection.

Key Points: 
  • The peer-reviewed publication reported efficacy data from a post-hoc analysis of the SAKURA Phase 3 clinical program that demonstrated significant, progressive improvement in static glabellar lines with repeated treatment of DaxibotulinumtoxinA for Injection.
  • The post-hoc analysis included 568 subjects with moderate or severe dynamic glabellar lines who were treated with three cycles of 40U of DaxibotulinumtoxinA for Injection in the SAKURA clinical program.
  • The results showed rapid and sustained improvement in static glabellar line severity following repeated treatment with DaxibotulinumtoxinA for Injection.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.